Concordance of genomic alterations between primary and recurrent breast cancer

Funda Meric-Bernstam, Garrett M. Frampton, Jaime Ferrer-Lozano, Roman Yelensky, Jose A. Pérez-Fidalgo, Ying Wang, Gary A. Palmer, Jeffrey S. Ross, Vincent A. Miller, Xiaoping Su, Pilar Eroles, Juan Antonio Barrera, Octavio Burgues, Ana M. Lluch, Xiaofeng Zheng, Aysegul Sahin, Philip J. Stephens, Gordon Mills, Maureen T. Cronin, Ana M. Gonzalez-Angulo

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

There is growing interest in delivering genomically informed cancer therapy. Our aim was to determine the concordance of genomic alterations between primary and recurrent breast cancer. Targeted next-generation sequencing was performed on formalin-fixed paraffin-embedded (FFPE) samples, profiling 3,320 exons of 182 cancer-related genes plus 37 introns from 14 genes often rearranged in cancer. Point mutations, indels, copynumber alterations (CNA), and select rearrangements were assessed in 74 tumors from 43 patients (36 primary and 38 recurrence/metastases). Alterations potentially targetable with established or investigational therapeutics were considered "actionable." Alterations were detected in 55 genes (mean 3.95 alterations/sample, range 1-12), including mutations in PIK3CA, TP53, ARID1A, PTEN, AKT1, NF1, FBXW7, and FGFR3 and amplifications in MCL1, CCND1, FGFR1,MYC, IGF1R,MDM2,MDM4, AKT3, CDK4, and AKT2. In 33 matched primary and recurrent tumors, 97 of 112 (86.6%) somatic mutations were concordant. Of identified CNAs, 136 of 159 (85.5%) were concordant: 37 (23.3%) were concordant, but below the reporting threshold in one of the matched samples, and 23 (14.5%) discordant. There was an increased frequency ofCDK4/MDM2amplifications in recurrences, as well as gains and losses of other actionable alterations. Forty of 43 (93%) patients had actionable alterations that could inform targeted treatment options. In conclusion, deep genomic profiling of cancer-related genes reveals potentially actionable alterations in most patients with breast cancer. Overall there was high concordance between primary and recurrent tumors. Analysis of recurrent tumors before treatment may provide additional insights, as both gains and losses of targets are observed.

Original languageEnglish (US)
Pages (from-to)1382-1389
Number of pages8
JournalMolecular Cancer Therapeutics
Volume13
Issue number5
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Breast Neoplasms
Neoplasms
Neoplasm Genes
Recurrence
Mutation
Therapeutics
Point Mutation
Paraffin
Introns
Formaldehyde
Genes
Exons
Neoplasm Metastasis

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Meric-Bernstam, F., Frampton, G. M., Ferrer-Lozano, J., Yelensky, R., Pérez-Fidalgo, J. A., Wang, Y., ... Gonzalez-Angulo, A. M. (2014). Concordance of genomic alterations between primary and recurrent breast cancer. Molecular Cancer Therapeutics, 13(5), 1382-1389. https://doi.org/10.1158/1535-7163.MCT-13-0482

Concordance of genomic alterations between primary and recurrent breast cancer. / Meric-Bernstam, Funda; Frampton, Garrett M.; Ferrer-Lozano, Jaime; Yelensky, Roman; Pérez-Fidalgo, Jose A.; Wang, Ying; Palmer, Gary A.; Ross, Jeffrey S.; Miller, Vincent A.; Su, Xiaoping; Eroles, Pilar; Barrera, Juan Antonio; Burgues, Octavio; Lluch, Ana M.; Zheng, Xiaofeng; Sahin, Aysegul; Stephens, Philip J.; Mills, Gordon; Cronin, Maureen T.; Gonzalez-Angulo, Ana M.

In: Molecular Cancer Therapeutics, Vol. 13, No. 5, 01.01.2014, p. 1382-1389.

Research output: Contribution to journalArticle

Meric-Bernstam, F, Frampton, GM, Ferrer-Lozano, J, Yelensky, R, Pérez-Fidalgo, JA, Wang, Y, Palmer, GA, Ross, JS, Miller, VA, Su, X, Eroles, P, Barrera, JA, Burgues, O, Lluch, AM, Zheng, X, Sahin, A, Stephens, PJ, Mills, G, Cronin, MT & Gonzalez-Angulo, AM 2014, 'Concordance of genomic alterations between primary and recurrent breast cancer', Molecular Cancer Therapeutics, vol. 13, no. 5, pp. 1382-1389. https://doi.org/10.1158/1535-7163.MCT-13-0482
Meric-Bernstam F, Frampton GM, Ferrer-Lozano J, Yelensky R, Pérez-Fidalgo JA, Wang Y et al. Concordance of genomic alterations between primary and recurrent breast cancer. Molecular Cancer Therapeutics. 2014 Jan 1;13(5):1382-1389. https://doi.org/10.1158/1535-7163.MCT-13-0482
Meric-Bernstam, Funda ; Frampton, Garrett M. ; Ferrer-Lozano, Jaime ; Yelensky, Roman ; Pérez-Fidalgo, Jose A. ; Wang, Ying ; Palmer, Gary A. ; Ross, Jeffrey S. ; Miller, Vincent A. ; Su, Xiaoping ; Eroles, Pilar ; Barrera, Juan Antonio ; Burgues, Octavio ; Lluch, Ana M. ; Zheng, Xiaofeng ; Sahin, Aysegul ; Stephens, Philip J. ; Mills, Gordon ; Cronin, Maureen T. ; Gonzalez-Angulo, Ana M. / Concordance of genomic alterations between primary and recurrent breast cancer. In: Molecular Cancer Therapeutics. 2014 ; Vol. 13, No. 5. pp. 1382-1389.
@article{ed50fdafbd5543f1a4240362b7ff2b22,
title = "Concordance of genomic alterations between primary and recurrent breast cancer",
abstract = "There is growing interest in delivering genomically informed cancer therapy. Our aim was to determine the concordance of genomic alterations between primary and recurrent breast cancer. Targeted next-generation sequencing was performed on formalin-fixed paraffin-embedded (FFPE) samples, profiling 3,320 exons of 182 cancer-related genes plus 37 introns from 14 genes often rearranged in cancer. Point mutations, indels, copynumber alterations (CNA), and select rearrangements were assessed in 74 tumors from 43 patients (36 primary and 38 recurrence/metastases). Alterations potentially targetable with established or investigational therapeutics were considered {"}actionable.{"} Alterations were detected in 55 genes (mean 3.95 alterations/sample, range 1-12), including mutations in PIK3CA, TP53, ARID1A, PTEN, AKT1, NF1, FBXW7, and FGFR3 and amplifications in MCL1, CCND1, FGFR1,MYC, IGF1R,MDM2,MDM4, AKT3, CDK4, and AKT2. In 33 matched primary and recurrent tumors, 97 of 112 (86.6{\%}) somatic mutations were concordant. Of identified CNAs, 136 of 159 (85.5{\%}) were concordant: 37 (23.3{\%}) were concordant, but below the reporting threshold in one of the matched samples, and 23 (14.5{\%}) discordant. There was an increased frequency ofCDK4/MDM2amplifications in recurrences, as well as gains and losses of other actionable alterations. Forty of 43 (93{\%}) patients had actionable alterations that could inform targeted treatment options. In conclusion, deep genomic profiling of cancer-related genes reveals potentially actionable alterations in most patients with breast cancer. Overall there was high concordance between primary and recurrent tumors. Analysis of recurrent tumors before treatment may provide additional insights, as both gains and losses of targets are observed.",
author = "Funda Meric-Bernstam and Frampton, {Garrett M.} and Jaime Ferrer-Lozano and Roman Yelensky and P{\'e}rez-Fidalgo, {Jose A.} and Ying Wang and Palmer, {Gary A.} and Ross, {Jeffrey S.} and Miller, {Vincent A.} and Xiaoping Su and Pilar Eroles and Barrera, {Juan Antonio} and Octavio Burgues and Lluch, {Ana M.} and Xiaofeng Zheng and Aysegul Sahin and Stephens, {Philip J.} and Gordon Mills and Cronin, {Maureen T.} and Gonzalez-Angulo, {Ana M.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1158/1535-7163.MCT-13-0482",
language = "English (US)",
volume = "13",
pages = "1382--1389",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Concordance of genomic alterations between primary and recurrent breast cancer

AU - Meric-Bernstam, Funda

AU - Frampton, Garrett M.

AU - Ferrer-Lozano, Jaime

AU - Yelensky, Roman

AU - Pérez-Fidalgo, Jose A.

AU - Wang, Ying

AU - Palmer, Gary A.

AU - Ross, Jeffrey S.

AU - Miller, Vincent A.

AU - Su, Xiaoping

AU - Eroles, Pilar

AU - Barrera, Juan Antonio

AU - Burgues, Octavio

AU - Lluch, Ana M.

AU - Zheng, Xiaofeng

AU - Sahin, Aysegul

AU - Stephens, Philip J.

AU - Mills, Gordon

AU - Cronin, Maureen T.

AU - Gonzalez-Angulo, Ana M.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - There is growing interest in delivering genomically informed cancer therapy. Our aim was to determine the concordance of genomic alterations between primary and recurrent breast cancer. Targeted next-generation sequencing was performed on formalin-fixed paraffin-embedded (FFPE) samples, profiling 3,320 exons of 182 cancer-related genes plus 37 introns from 14 genes often rearranged in cancer. Point mutations, indels, copynumber alterations (CNA), and select rearrangements were assessed in 74 tumors from 43 patients (36 primary and 38 recurrence/metastases). Alterations potentially targetable with established or investigational therapeutics were considered "actionable." Alterations were detected in 55 genes (mean 3.95 alterations/sample, range 1-12), including mutations in PIK3CA, TP53, ARID1A, PTEN, AKT1, NF1, FBXW7, and FGFR3 and amplifications in MCL1, CCND1, FGFR1,MYC, IGF1R,MDM2,MDM4, AKT3, CDK4, and AKT2. In 33 matched primary and recurrent tumors, 97 of 112 (86.6%) somatic mutations were concordant. Of identified CNAs, 136 of 159 (85.5%) were concordant: 37 (23.3%) were concordant, but below the reporting threshold in one of the matched samples, and 23 (14.5%) discordant. There was an increased frequency ofCDK4/MDM2amplifications in recurrences, as well as gains and losses of other actionable alterations. Forty of 43 (93%) patients had actionable alterations that could inform targeted treatment options. In conclusion, deep genomic profiling of cancer-related genes reveals potentially actionable alterations in most patients with breast cancer. Overall there was high concordance between primary and recurrent tumors. Analysis of recurrent tumors before treatment may provide additional insights, as both gains and losses of targets are observed.

AB - There is growing interest in delivering genomically informed cancer therapy. Our aim was to determine the concordance of genomic alterations between primary and recurrent breast cancer. Targeted next-generation sequencing was performed on formalin-fixed paraffin-embedded (FFPE) samples, profiling 3,320 exons of 182 cancer-related genes plus 37 introns from 14 genes often rearranged in cancer. Point mutations, indels, copynumber alterations (CNA), and select rearrangements were assessed in 74 tumors from 43 patients (36 primary and 38 recurrence/metastases). Alterations potentially targetable with established or investigational therapeutics were considered "actionable." Alterations were detected in 55 genes (mean 3.95 alterations/sample, range 1-12), including mutations in PIK3CA, TP53, ARID1A, PTEN, AKT1, NF1, FBXW7, and FGFR3 and amplifications in MCL1, CCND1, FGFR1,MYC, IGF1R,MDM2,MDM4, AKT3, CDK4, and AKT2. In 33 matched primary and recurrent tumors, 97 of 112 (86.6%) somatic mutations were concordant. Of identified CNAs, 136 of 159 (85.5%) were concordant: 37 (23.3%) were concordant, but below the reporting threshold in one of the matched samples, and 23 (14.5%) discordant. There was an increased frequency ofCDK4/MDM2amplifications in recurrences, as well as gains and losses of other actionable alterations. Forty of 43 (93%) patients had actionable alterations that could inform targeted treatment options. In conclusion, deep genomic profiling of cancer-related genes reveals potentially actionable alterations in most patients with breast cancer. Overall there was high concordance between primary and recurrent tumors. Analysis of recurrent tumors before treatment may provide additional insights, as both gains and losses of targets are observed.

UR - http://www.scopus.com/inward/record.url?scp=84899837889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899837889&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-13-0482

DO - 10.1158/1535-7163.MCT-13-0482

M3 - Article

C2 - 24608573

AN - SCOPUS:84899837889

VL - 13

SP - 1382

EP - 1389

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 5

ER -